Welcome to the new academic journal OBM Hepatology and Gastroenterology. Recent progress in understanding liver, biliary, pancreatic and gastro-intestinal diseases and their treatments has been observed in the world. OBM Hepatology and Gastroenterology publishes interesting and informative reviews, original articles, and invaluable case reports in this area. We also publish basic research as well as clinical research.

Hepatitis A virus (HAV), HBV, HCV, HDV, and HEV are still a serious issue worldwide. Treatments on these viruses have recently improved. However, liver fibrosis, cirrhosis and hepatocellular carcinoma are still critical conditions. We focus on all of these liver diseases. We also focus on broad-spectrum of gastro-intestinal diseases in this journal.

Please accept our special thanks for choosing to publish in the OBM Hepatology and Gastroenterology. We are looking forward to your submissions for OBM Hepatology and Gastroenterology.

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 6.8 days from acceptance to publication (median values for papers published in this journal in 2020, 1-2 days of FREE language polishing time is also included in this period).

Free Publication in 2021
Current Issue: 2021  Archive: 2020 2019 2018 2017

Special Issue

Helicobacter Infection and Digestive Cancer

Submission Deadline: September 30, 2020 (Open) Submit Now

Guest Editor

Luis Rodrigo, Ph.D

Professor of Medicine, Department of Gastroenterology, University of Oviedo, Oviedo, Asturias, Spain

Website | E-Mail

Research Interests: Colon Cancer; hepatocellular carcinoma; liver cirrhosis; celiac disease; autoimmune related diseases; neurologic diseases gluten-related; rheumatologic diseases; sepsis; infectious diseases

About This Topic

Helicobacter pylori (Hp) chronic infection, is mainly associated with the development of two types of gastric tumors, such as Adenocarcinoma (GA) and MALT Lymphomas. The relative risk for the development of gastric adenocarcinoma in infected subjects, is 3 to 6 times higher compared to those not infected. Epidemiologically a risk attracted to this bacterium, is estimated for its development, in 30 to 60% of total cases. This implies that the elimination of this infection, would prevent the subsequent appearance of the tumor, in the same proportion of cases theoretically. In 1994 the World Health Organization classified the relationship between the Hp infection and gastric cancer as grade I, which is equivalent to consider this germ as a causative factor. However, it is estimated that only 0.5% of people infected with Hp present a GA, which clearly confirms the multifactorial nature of gastric carcinogenesis.
The normal stomach lacks organized lymphoid tissue and Hp chronic infection is the main cause of its appearance. The chronic immunological stimulation maintained by this bacterium, together with environmental and host factors, produces the appearance of a low-grade MALT, which could be transformed into a high-grade. This relationship Hp-gastric MALT lymphoma has been demonstrated extensively by epidemiological, histological, immunological and response studies to the eradication treatment, considered as of choice for this type of tumors.